Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
Breakthrough in oral TB vaccine
Jun. 2, 2012
In the phase II study by Immunitor, people with tuberculosis were given the oral vaccine alongside TB drugs. After just one month, almost 80% of the vaccinated patients showed no M. vaccae in their sputum smears, while under 20% in the placebo group. The results indicate that conventional TB therapy can be shortened significantly.
New method to develop safer and more effective vaccines
Jun. 5, 2012
According to Nature Medicine, an Oregon-based biotech company, Najít Technologies, used a simple solution of hydrogen peroxide to inactivate viruses, and created inactivated vaccines against West Nile virus, lymphocytic choriomeningitis virus and vaccinia virus. All three triggered protective vaccine-induced immunity.
Screenshot of media report
Jun. 8, 2012
The joint-venture of BravoBio and Chinese Academy of Sciences, Wuhan Zhongke BravoBio, was reported by Hubei provincial media—Chutian Metropolis Daily at page 70, Jun. 1, 2012. The recombinant EV71 vaccine against human hand-foot-and-mouth disease is under development with promising results in this JV.
Two-valent meningitis vaccine approved in US-FDA
Jun. 15, 2012
Developed by GSK, the MenHibrix vaccine will be used against Neisseria meningitidis and Haemophilus influenzae type b bacterial diseases. It is the first of its kind that can be given to infants as young as 1.5 months old.
5th Annual BioPharma China Convention held in Beijing
Jun. 24, 2012
Delegates gathered in Beijing Marriott Hotel Northeast to attend the convention focused in vaccine and antibody. Dr Wu Ke was invited to be a moderator to host a panel discussion on "How do Chinese Vaccine Producers Head for International Market —Getting Prepared for WHO Vaccine Pre-qualification".
New HPV vax could treat cancer rather than prevent it
Jun. 29, 2012
Professor Ian Frazer and his fellow scientists have created a synthetic vaccine called TriVax, which includes a fragment of the HPV16-E7 protein, anti-CD40 antibodies and an adjuvant. The result of the animal study using mice with HPV16-induced tumors shows that the vaccine triggered a large and long-lasting T cell response and eradicated the tumors completely in most of the mice, while the tumors in the placebo group continued to grow.
The European Medicines Agency finalizes Pharmacovigilance Guidelines
Jul. 5, 2012
EMA has published its first set of finalized guidelines for good pharmacovigilance practices (GVP). Seven modules have been finalized regarding pharmacovigilance systems and their quality systems, pharmacovigilance systems' master files, risk-management systems, management and reporting of adverse drug reactions to medicinal products, periodic safety update reports, postauthorization safety studies, and signal management.
Australia plans to give HPV vax Gardasil to boys
Jul. 12, 2012
Australia government takes the lead to give boys ages 12 and 13 the three-round dose of Gardasil vaccine, a HPV vaccine from Merck, under the national immunization program. With up to 870,000 vaccinations in four years, the program is about to cost $21.1 million.
Gene therapy to be approved in Western countries
Jul. 20, 2012
The Dutch biotech uniQure got green light from EMA for its gene therapy, Glybera, to treat severe cases of lipoprotein lipase deficiency (LPLD). uniQure plans to seek approvals for Glybera in the North America next.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next